Literature DB >> 9630015

Quinuclidinium-imidazolium compounds: synthesis, mode of interaction with acetylcholinesterase and effect upon Soman intoxicated mice.

V Simeon-Rudolf1, E Reiner, M Skrinjarić-Spoljar, B Radić, A Lucić, I Primozic, S Tomić.   

Abstract

Four compounds were prepared: 3-oxo-1-methylquinuclidinium iodide (I), 2-hydroxyiminomethyl-1,3-dimethylimidazolium iodide (II) and two conjugates of I and II linked by -(CH2)3- (III) and -CH2-O-CH2- (IV). The aim was to evaluate separately the properties of I and II as opposed to III and IV, which contain both moieties in the same molecule. All four compounds were reversible inhibitors of acetylcholinesterase (AChE; EC 3.1.1.7). The enzyme/inhibitor dissociation constants for the catalytic site ranged from 0.073 mM (II) to 1.6 mM (I). The dissociation constant of I for the allosteric (substrate inhibition) site was 4.8 mM. Possible binding of the other compounds to the allosteric site could not be measured because II, III and IV reacted with the substrate acetylthiocholine (ATCh) and at high ATCh concentrations the non-enzymic reaction interfered with the enzymic hydrolysis of ATCh. The rate constants for the non-enzymic ATCh hydrolysis were between 23 and 37 l/mol per min. All four compounds protected AChE against phosphorylation by Soman and VX. The protective index (PI) of I (calculated from binding of I to both, catalytic and allosteric sites in AChE) agreed with the measured PI; this confirms that allosteric binding contributes to the decrease of phosphorylation rates. The PI values obtained with III and IV were higher than those predicted by the assumption of their binding to the AChE catalytic site only. The toxicity (i.p. LD50) of compounds I, II, III and IV for mice was 0.21, 0.68, 0.49 and 0.77 mmol/kg body wt. respectively. All four compounds protected mice against Soman when given (i.p.) together with atropine 1 min after Soman (s.c.). One-quarter of the LD50 dose fully protected mice (survival of all animals) against 2.52 (IV), 2.00 (I and III) and 1.58 (II) LD50 doses of Soman.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630015     DOI: 10.1007/s002040050504

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  6 in total

1.  The acute toxicity of acetylcholinesterase reactivators in mice in relation to their structure.

Authors:  Lucie Bartosova; Kamil Kuca; Gabriela Kunesova; Daniel Jun
Journal:  Neurotox Res       Date:  2006-06       Impact factor: 3.911

2.  Synthesis of new N-quaternary-3-benzamidoquinuclidinium salts.

Authors:  Renata Odzak; Srdjanka Tomic
Journal:  Molecules       Date:  2006-09-28       Impact factor: 4.411

3.  Novel Imidazole Aldoximes with Broad-Spectrum Antimicrobial Potency against Multidrug Resistant Gram-Negative Bacteria.

Authors:  Mirjana Skočibušić; Renata Odžak; Alma Ramić; Tomislav Smolić; Tomica Hrenar; Ines Primožič
Journal:  Molecules       Date:  2018-05-18       Impact factor: 4.411

4.  Tuning Butyrylcholinesterase Inactivation and Reactivation by Polymer-Based Protein Engineering.

Authors:  Libin Zhang; Stefanie L Baker; Hironobu Murata; Nicholas Harris; Weihang Ji; Gabriel Amitai; Krzysztof Matyjaszewski; Alan J Russell
Journal:  Adv Sci (Weinh)       Date:  2019-11-13       Impact factor: 16.806

5.  Imidazole aldoximes effective in assisting butyrylcholinesterase catalysis of organophosphate detoxification.

Authors:  Rakesh K Sit; Valery V Fokin; Gabriel Amitai; K Barry Sharpless; Palmer Taylor; Zoran Radić
Journal:  J Med Chem       Date:  2014-02-07       Impact factor: 7.446

6.  Quinuclidine-Based Carbamates as Potential CNS Active Compounds.

Authors:  Ana Matošević; Andreja Radman Kastelic; Ana Mikelić; Antonio Zandona; Maja Katalinić; Ines Primožič; Anita Bosak; Tomica Hrenar
Journal:  Pharmaceutics       Date:  2021-03-20       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.